ORPHAN Cures Act

This bill amends the Drug Price Negotiation Program to better support orphan drugs (medications for rare diseases). It changes how time is calculated for orphan drugs by excluding periods when a drug was designated as an orphan from the timeline used to determine when price negotiations begin. The bill also updates definitions to allow a single drug to cover multiple rare diseases, rather than being limited to just one disease. This directly affects pharmaceutical companies developing treatments for rare conditions, giving them more time before their drugs enter the price negotiation process. The changes aim to encourage continued development of therapies for small patient populations.